课题基金 / 基金详情

Identification of Cell Type-Specific Actions of Antipsychotic Drugs

Identification of Cell Type-Specific Actions of Antipsychotic Drugs
抗精神病药物的细胞类型特异性作用的鉴定
批准号:
8151096
负责人:
PAUL GREENGARD
金额:
$197.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-29 至 2015-04-30

项目摘要

项目成果

PAUL GREENGARD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Schizophrenia is one of the most debilitating psychiatric disorders, affecting approximately 1% of the population worldwide. A number of antipsychotic drugs are available but these are often ineffective and do not treat all the symptoms of the disease. New therapeutics are needed but their discovery has been hampered by a limited understanding of the etiology of this complex neurological disorder, and a lack of clear understanding of the precise molecular mechanisms of action of available antipsychotic drugs. One of the major limitations in identifying the molecular mechanisms of antipsychotic drug action has been the heterogeneous and intermixed cellular nature of the central nervous system. The major goal of the proposed studies in the Conte Center is therefore to achieve a complete understanding of the cellular and molecular actions of antipsychotic drugs through innovative approaches that use novel rodent animal models to allow analysis of individual types of neurons within cortico-striatal circuits. The Center Director and leader of Project 1 is Paul Greengard (Rockefeller University). The other Project leaders are: Nathaniel Heintz (Project 2, Rockefeller University); Angus Nairn (Project 3, Yale University); Eric Nestler (Project 4, Mount Sinai Medical School); and James Surmeier (Project 5, Northwestern University. There will also be an Animal Core, a Molecular & Biochemical Reagents Core, and an Administrative Core. The five Pis involved have an established history of effective collaboration and will use their complementary expertise and resources to take a multi-disciplinary approach in the proposed research. Through the use of biochemical, cell biological, molecular, electrophysiological, structural and behavioral assays, the proposed Conte Center will achieve a fuller understanding of the cellular and molecular actions of antipsychotic drugs in the cortico-striatal circuits. PUBLIC HEALTH RELEVANCE: Relevance to public health: Schizophrenia is a debilitating psychiatric disorder, and new therapies are needed. This Conte Center will characterize the effects of antipsychotic drugs on the properties of specific neuronal subtypes involved in schizophrenia, allowing for a complete understanding of the normal and maladaptive actions of these drugs, and leading to better therapies with higher efficacy and fewer side-effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MECHANISMS FOR SELECTIVE REGULATION OF GAMMA-SECRETASE (AG09464-21A1 PROJ 2
  • 批准号:
    8724095
  • 项目类别:
  • 资助金额:
    $57.67万
  • 财政年份:
    2013
  • 负责人:
    PAUL GREENGARD
  • 依托单位:
MECHANISMS FOR SELECTIVE REGULATION OF GAMMA-SECRETASE (AG09464-21A1 PROJ 2
  • 批准号:
    8735057
  • 项目类别:
  • 资助金额:
    $57.67万
  • 财政年份:
    2013
  • 负责人:
    PAUL GREENGARD
  • 依托单位:
P2 - Role of mGluR5/CK1-CK2/DARPP-32 Pathway in Psychostimulant Effects
  • 批准号:
    8334266
  • 项目类别:
  • 资助金额:
    $32.58万
  • 财政年份:
    2011
  • 负责人:
    PAUL GREENGARD
  • 依托单位:
IDENTIFICATION OF PHOSPHORYLATION SITES ON GLUTAMATE RECEPTOR MGLUR5
  • 批准号:
    8361517
  • 项目类别:
  • 资助金额:
    $0.13万
  • 财政年份:
    2011
  • 负责人:
    PAUL GREENGARD
  • 依托单位:
国内基金
海外基金
全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
  • 批准号:
    QN25H220002
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    顾媛
  • 依托单位:
染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    王锐智
  • 依托单位:
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造 血干细胞生成中的作用及机制研究
  • 批准号:
    TGY24H080011
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    李鸿鹄
  • 依托单位:
基于In-cell NMR策略对“舟楫之剂”桔梗中引经药效物质的快速发现研究
  • 批准号:
    82305053
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    王丽明
  • 依托单位: